Polatuzumab outperforms pinatuzumab in non-Hodgkin lymphomaApril 5, 2019Lymphoma & Plasma Cell Disorders
Early data support R-BAC for post-BTKi mantle cell lymphomaApril 5, 2019Lymphoma & Plasma Cell Disorders
ASCO, CCO issue multiple myeloma treatment guidelinesApril 4, 2019Multiple MyelomaLymphoma & Plasma Cell Disorders
Real world responses mirror TOURMALINE-MM1 dataApril 4, 2019Multiple MyelomaLymphoma & Plasma Cell Disorders
Combo could replace standard conditioning regimen for myelomaApril 2, 2019Multiple MyelomaLymphoma & Plasma Cell Disorders
High survival in relapsed FL after primary radiotherapyMarch 21, 2019Lymphoma & Plasma Cell Disorders
Oral triplet deemed effective in relapsed/refractory myelomaMarch 13, 2019Multiple MyelomaLymphoma & Plasma Cell Disorders
Therapeutic dosing of busulfan helps reduce relapse in ASCTMarch 13, 2019TransplantationAggressive LymphomasLymphoma & Plasma Cell Disorders
Myeloma risk score has treatment-planning potentialMarch 12, 2019Multiple MyelomaLymphoma & Plasma Cell Disorders
Bendamustine-rituximab shines in frontline treatment of MCL, iNHLMarch 8, 2019Lymphoma & Plasma Cell Disorders
